Avello Alejandro, Fernandez-Prado Raul, Santos-Sanchez-Rey Begoña, Rojas-Rivera Jorge, Ortiz Alberto
Department of Medicine, School of Medicine, IIS-Fundación Jiménez Diaz, Division of Nephrology and Hypertension, Universidad Autónoma de Madrid, Madrid, Spain.
Red de Investigación Renal (REDINREN), Instituto Carlos III-FEDER, Madrid, Spain.
Clin Kidney J. 2020 Nov 9;14(1):18-22. doi: 10.1093/ckj/sfaa181. eCollection 2021 Jan.
Nephrologists are familiar with severe cases of anti-neutrophil cytoplasmic antibodies-associated vasculitis (AAV) presenting as rapidly progressive glomerulonephritis. However, less is known about AAV with slowly progressive renal involvement. While its existence is acknowledged in textbooks, much remains unknown regarding its relative frequency versus more aggressive cases as well as about the optimal therapeutic approach and response to therapy. Moreover, this uncommon presentation may be underdiagnosed, given the scarce familiarity of physicians. In this issue of , Trivioli . report the largest series to date and first systematic assessment of patients with AAV and slowly progressive renal involvement, defined as a reduction in estimated glomerular filtration rate (eGFR) of 25-50% in the 6 months prior to diagnosis after excluding secondary causes. Key findings are that slowly progressive AAV may be less common than previously thought, although it still represents the second most common presentation of renal AAV, it usually has a microscopic polyangiitis, anti-myeloperoxidase, mainly renal phenotype in elderly individuals, diagnosis may be late (over one-third of patients had end-stage kidney disease at diagnosis), clearly identifying an unmet need for physician awareness about this presentation, but those not needing renal replacement therapy at diagnosis still responded to immunosuppression.
肾病学家对以快速进展性肾小球肾炎形式出现的抗中性粒细胞胞浆抗体相关性血管炎(AAV)的严重病例很熟悉。然而,对于肾脏受累进展缓慢的AAV了解较少。虽然其在教科书中已被认可,但关于其与更具侵袭性病例相比的相对发生率,以及最佳治疗方法和对治疗的反应,仍有很多未知之处。此外,鉴于医生对此了解甚少,这种不常见的表现可能未被充分诊断。在本期杂志中,特里维奥利等人报告了迄今为止最大规模的系列研究,并首次对肾脏受累进展缓慢的AAV患者进行了系统评估,该疾病定义为在排除继发原因后,诊断前6个月内估计肾小球滤过率(eGFR)下降25% - 50%。主要发现是,进展缓慢的AAV可能比之前认为的更少见,尽管它仍是肾脏AAV的第二常见表现形式,它通常具有显微镜下多血管炎、抗髓过氧化物酶,在老年个体中主要表现为肾脏受累,诊断可能较晚(超过三分之一的患者在诊断时已处于终末期肾病),这明确表明医生对这种表现形式的认识存在未满足的需求,但那些在诊断时不需要肾脏替代治疗的患者对免疫抑制治疗仍有反应。